WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended September 30, 2015, and provided a business update.
“This has been a productive quarter as we continue enrollment in the GENETIC-AF trial evaluating Gencaro as a potential treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and CEO.
Help employers find you! Check out all the jobs and post your resume.
“This has been a productive quarter as we continue enrollment in the GENETIC-AF trial evaluating Gencaro as a potential treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and CEO.
Help employers find you! Check out all the jobs and post your resume.
